Navigation Links
High Rates of Pathological Complete Response in Patients with Advanced Esophageal Cancer in OPAXIO™ Phase II Study Reported in American Journal of Clinical Oncology
Date:2/23/2011

SEATTLE, Feb. 23, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that updated phase II study results of OPAXIO (paclitaxel poliglumex) in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% (15/40) of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.  A pathological complete response, observed in 32% of patients in the study, is recorded only when the esophagus is surgically removed after therapy and no tumor can be found microscopically.  In historical studies, pathologic complete response has correlated with prolonged survival.

"We are pleased to have the impressive and potentially important results of the paclitaxel poliglumex phase II esophageal study published in a peer reviewed journal," said Dr. Howard Safran, M.D., director of the Brown University Oncology Group.  "In this study, the treatment was well tolerated and we did not see the severe side effects that are typically experienced with standard treatment options.  If these data can be validated in a randomized controlled trial, the use of paclitaxel poliglumex along with cisplatin and radiation could provide an important treatment alternative for patients with lower esophageal cancer with an attractive risk-benefit profile."

The phase II study conducted by the Brown University Oncology Group enrolled 40 patients with pathologically-confirmed, locally-advanced adenocarcinoma or squamous cell carcinoma of the esophagus or gastro-esophageal junction with no evidence of distant metastases.  The patients received weekly paclitaxel poliglumex (50mg/m2) and cisplatin (25mg/m2) for six weeks with concurrent 50.5Gy of radiation. The updated data demonstrated
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. GlaxoSmithKline Accelerates Review of Exelixis XL880
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
9. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
10. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
11. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
(Date:8/29/2014)... -- , Industry professionals and media ... taking place in real-time at CPhI Worldwide  ... UBM Live , announces the launch of #CPhIChat ... its kind global industry-wide Tweetchat for pharma professionals ... to stimulate conversations on key industry issues and ...
(Date:8/28/2014)... Long, P.A.: , Do you, or did you, ... , Did you purchase your shares before September 10, 2013, ... , Did you lose money in your investment in Lannett ... rights? Rigrodsky & Long, P.A. , ... , announces that a complaint has been filed in the United ...
Breaking Medicine Technology:DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
(Date:8/30/2014)... Franklin, TN (PRWEB) August 30, 2014 ... techniques, including nine mobilizations and six muscle energy techniques. ... also narrates and demonstrates twenty-seven examination techniques for the ... course supports Dr. Reiman's live course presentation with ... Objectives, Applying a differential diagnosis ...
(Date:8/30/2014)... 2014 The KSF (Kung Fu Sanshou ... Search on November 8th, 2014 at the Mobile Civic ... have introduced many notorious and notable fighters for some ... the UFC. , Among these KSF along with ... doors armed with the virtues of true indomitable Shaolin ...
(Date:8/30/2014)... 30 August 2014: The first multidisciplinary recommendations on ... coronary syndromes (ACS) are published today in ... written jointly by the European Heart Rhythm Association ... the European Association of Percutaneous Cardiovascular Interventions (EAPCI), ... Gorenek (Turkey), chairperson of the task force, said: ...
(Date:8/30/2014)... Spain Saturday 30 August 2014: The first ... anticoagulants in pulmonary embolism are published today in ... ESC Congress by Professor Stavros V. Konstantinides (Germany/Greece) ... ESC Guidelines on the diagnosis and management of ... European Heart Journal (1) and on the ESC ...
(Date:8/29/2014)... Daily Gossip writes in its review that this ... nowadays. This method promises to teach readers how to eliminate ... effective alternative sources for the production of energy. , ... and solar power. , The Home Made Energy review ... eBook. So, this is an online guide that will teach ...
Breaking Medicine News(10 mins):Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 2Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 3Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 4Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2Health News:First recommendations on all new oral anticoagulants in pulmonary embolism published 2Health News:Home Made Energy Review Exposes Simple Method to Access Alternative Energy Sources 2
... and improves ... customer ... subsidiary of Hays plc., one of the world,s leading specialist,recruitment ... processes and improve customer service., Hays stated that it ...
... in the United States, WARSAW, Ind., Jan. ... SWX: ZMH), a leader in the orthopaedic industry, ... have been completed in,the United States. The Zimmer ... the rigid stabilization of the OPTIMA(TM) ZS,Spinal System ...
... WILMINGTON, Del., Jan. 8 DuPont (NYSE: ... Environmental Protection,Agency for Agility(TM) SG herbicide, a new ... tool for broad spectrum weed control, including,ALS resistant ... modes of action in a single formulation to ...
... could add 14 years, study says , , TUESDAY, ... lifestyle behaviors -- not smoking, physical activity, moderate alcohol ... a day -- live an average of 14 years ... new British study contends. , Researchers at the University ...
... millions of Americans are having to dig deeper into their own ... , The reason" Higher co-payments that took effect January 1, as ... by making employees and retirees pay more. , But a ... down at least for some people taking some drugs. , ...
... Jan. 7 Digirad Corporation,(Nasdaq: DRAD ), ... services to physicians, offices, hospitals and imaging centers, ... R. King Nelson, a,director and member of the ... today., Nelson, 50, has served on Digirad,s ...
Cached Medicine News:Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 2Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 3Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 4Health News:Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System 2Health News:Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System 3Health News:Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System 4Health News:New DuPont(TM) Agility(TM) SG Herbicide Offers Wheat Growers Answers to Changing Weed Control Needs 2Health News:Small Lifestyle Changes Can Boost Longevity 2Health News:Study proves the co-pay connection in chronic disease 2Health News:Study proves the co-pay connection in chronic disease 3Health News:Study proves the co-pay connection in chronic disease 4Health News:Digirad Corporation Board of Directors Appoints R. King Nelson Chairman 2Health News:Digirad Corporation Board of Directors Appoints R. King Nelson Chairman 3Health News:Digirad Corporation Board of Directors Appoints R. King Nelson Chairman 4
Digital Imaging for Optical Screening:,Diabetes, Glaucoma Macular Degeneration, and other retinal disease....
... Laboratory is a comprehensive, ... manages specimen data from ... tracking to final cumulative ... is a multi-module system ...
... optimal speed, efficiency and results, without the ... Most importantly, EZLink meets strategic laboratory network ... in the same facility - without sacrificing ... paperless laboratory, the network can be linked ...
... Windows NT client server system that combines ... power and high-speed volume required to meet ... industry experts, LabNet is structured to make ... and effective as possible. Our system can ...
Medicine Products: